US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) has failed to invalidate a fifth Kymab patent, covering genetically-modified mice used to produce human antibody therapeutics.
A September 2019 application at the US Patent Office’s appeal board failed to overturn four other patents held by the firm, part of a series covering this technology.
The Patent Trial & Appeal Board (PTAB) noted that the firm “has not demonstrated that the examiner materially erred in considering the prior art and arguments,” and Regeneron has not requested a re-hearing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze